Yes, Start Moderate- to High-Intensity Statin Therapy
This patient should be started on high-intensity statin therapy immediately, as documented abdominal aortic atherosclerosis qualifies them as having clinical atherosclerotic cardiovascular disease (ASCVD), regardless of their zero coronary calcium score. 1, 2
Why the Zero Calcium Score Doesn't Change Management
The coronary artery calcium (CAC) score of zero is irrelevant in this clinical scenario because:
Abdominal aortic atherosclerosis is clinical ASCVD by definition 1. The 2018 ACC/AHA guidelines explicitly state that clinical ASCVD includes "peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin."
CAC scoring is a tool for primary prevention risk stratification only 3, 4. Once a patient has documented atherosclerotic disease in any vascular territory, they transition to secondary prevention, where CAC scoring no longer guides treatment decisions.
The presence of atherosclerosis in the abdominal aorta indicates systemic atherosclerotic burden, even when coronary calcification is absent 5, 6. Studies in psoriatic disease demonstrate moderate correlation between different vascular territories, with 48% of patients without carotid plaques still having femoral involvement 6.
Guideline-Directed Therapy
For patients ≤75 years of age with clinical ASCVD:
- High-intensity statin therapy is Class I, Level A recommendation 1
- Target: ≥50% reduction in LDL-C from baseline
- Goal: LDL-C <70 mg/dL (1.8 mmol/L) 1
If patient is >75 years of age:
- Moderate- to high-intensity statin remains reasonable (Class IIa) after evaluating potential benefits, adverse effects, drug interactions, frailty, and patient preferences 1
The Psoriatic Arthritis Factor
Psoriatic arthritis adds another layer of cardiovascular risk through:
- Chronic systemic inflammation driving endothelial dysfunction 7
- Increased incidence of acute myocardial infarction and cerebrovascular events 7
- Underestimated cardiovascular risk by traditional assessment tools 7
This inflammatory burden further justifies aggressive lipid-lowering therapy, as the patient has both anatomic atherosclerosis and an inflammatory condition that accelerates atherosclerotic disease.
Treatment Algorithm
Initiate high-intensity statin (atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) 8
Recheck lipid panel in 4-12 weeks to assess:
- LDL-C reduction (target ≥50%)
- Absolute LDL-C level (goal <70 mg/dL)
- Adherence and tolerability 9
If LDL-C remains ≥70 mg/dL on maximally tolerated statin:
For very high-risk features (multiple major ASCVD events or one major event plus multiple high-risk conditions):
Common Pitfalls to Avoid
Do not be falsely reassured by CAC = 0 in the presence of documented atherosclerosis elsewhere. While CAC = 0 in primary prevention suggests low near-term risk 11, 12, it does not exclude:
- Non-calcified plaque in coronary arteries 13, 14
- Atherosclerotic disease in other vascular beds (already documented in this patient)
- Future cardiovascular events, particularly in inflammatory conditions
Do not delay statin initiation for additional testing. The patient already meets criteria for secondary prevention based on abdominal aortic atherosclerosis.
Do not use moderate-intensity statin when high-intensity is tolerated. The 2024 ESC guidelines and 2024 ACC/AHA PAD guidelines both emphasize high-intensity statins for established ASCVD 8, 2, with meta-analyses showing 15% additional reduction in major vascular events compared to moderate-intensity therapy 1.
Evidence Strength
The recommendation for high-intensity statin therapy in this patient is supported by:
- Class I (strong), Level A (high-quality) evidence from multiple large randomized trials and meta-analyses 1, 2
- Consistent recommendations across 2018 ACC/AHA, 2024 ESC, and 2024 PAD guidelines
- Specific evidence in PAD populations showing 30% reduction in major adverse limb events and 39% reduction in all-cause mortality 2